Healthy Male Clinical Trial
Official title:
An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [14C]-LY3549492 in Healthy Participants
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 ([14C] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive [14C] LY3549492 given into a vein. The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath. The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04135898 -
A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects
|
Phase 1 | |
| Completed |
NCT02395926 -
To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT05849311 -
Phase I Trial of Envafolimab for Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT06105255 -
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
|
Phase 1 | |
| Completed |
NCT01651234 -
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT01359618 -
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
|
Phase 1 | |
| Completed |
NCT02395913 -
Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)
|
Phase 1 | |
| Completed |
NCT05202912 -
Food Effect Study of IDX-1197 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04828265 -
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
|
Phase 1 |